Ellagic Acid Administration Negated the Development of Streptozotocin-Induced Memory Deficit in Rats

Abstract

Rampant production of pro-oxidants and inadequate antioxidant availability in brain exert oxidative stress, which in synergism with impaired glucose metabolism and inflammation leads to neurodegeneration and cognitive deficits. Ellagic acid (EGA) is a phenolic compound present in various fruits and is reported to possess robust antioxidant and anti-inflammatory properties. The present study investigated the effect of EGA administration on streptozotocin (STZ) induced dementia in rats. Bilateral intracerebroventricle (ICV) injection of STZ (3 mg/kg) was given to Wistar rats (200 g) on day 1 and 3. EGA (17.5 and 35 mg/kg) was administered orally to rats for 28 days daily. The spatial memory of rats was quantified by using Morris water maze and elevated plus maze. Brain TBARS, GSH and TNF-α were also measured. Administration of EGA prevented the induction of STZ-ICV triggered cognitive deficits as evident by a significant (p<0.05) reduction in mean escape latency during acquisition trial and increased (p<0.05) time spent in target quadrant during retrieval trial in Morris water maze test, and reduction (p<0.05) in transfer latency in elevated plus maze test. Furthermore, both the doses of EGA attenuated STZ-ICV induced rise in brain TBARS as well as TNF-α and simultaneously enhanced the GSH content. Thus, EGA ameliorated STZ-induced dementia by probably restoring the balance between cellular pro-oxidants and anti-oxidants in brain of rats.

Key words

dementia - ellagic acid - oxidative stress - inflammation - memory

• References

• 1 Minati L, Edginton T, Bruzzone MG. et al. Current concepts in Alzheimer’s disease: A multidisciplinary review. Am J Alzheimers Dis Other Demen 2009; 24: 95-121 10.1177/1533317508328602
• 2 Kalaria RN, Maestre GE, Arizaga R. et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826 10.1016/S1474-4422(08)70169-8
• 3 Jahn H. Memory loss in Alzheimer’s disease. Dialogues Clin Neurosci 2013; 15: 445-454
• 4 Kamat PK, Kalani A, Rai S. et al. Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: A therapeutic intervention for treatment of sporadic Alzheimer’s disease (sAD)-like pathology. Mol Neurobiol 2016; 53: 4548-4562 10.1007/s12035-015-9384-y
• 5 de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 2014; 88: 548-559 10.1016/j.bcp.2013.12.012
• 6 Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer’s disease: current and future trends. Expert Rev Neurother 2015; 15: 3-5 10.1586/14737175.2015.990884
• 7 Eleazu CO, Eleazu KC, Chukwuma S. et al. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord 2013; 12: 60 10.1186/2251-6581-12-60
• 8 Blokland A, Jolles J. Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. Pharmacol Biochem Behav 1994; 47: 833-837
• 9 Larrosa M, Garcia-Conesa MT, Espin JC. et al. Ellagitannins, ellagic acid and vascular health. Mol Aspects Med 2010; 31: 513-539 10.1016/j.mam.2010.09.005
• 10 Ahmed T, Setzer WN, Nabavi SF. et al. Insights into effects of ellagic acid on the nervous system: A mini review. Curr Pharm Des 2016; 22: 1350-1360
• 11 Yan L, Yin P, Ma C. et al. Method development and validation for pharmacokinetic and tissue distributions of ellagic acid using ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Molecules 2014; 19: 18923-18935 10.3390/molecules191118923
• 12 de Oliveira MR. The effects of ellagic acid on brain cells: A mechanistic view and future directions. Neurochem Res 2016; 41: 1219-1228 10.1007/s11064-016-1853-9
• 13 Mansouri MT, Farbood Y, Naghizadeh B. et al. Beneficial effects of ellagic acid against animal models of scopolamine- and diazepam-induced cognitive impairments. Pharm Biol 2016; 54: 1947-1953 10.3109/13880209.2015.1137601
• 14 Farbood Y, Sarkaki A, Dianat M. et al. Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury. Life Sci 2015; 124: 120-127 10.1016/j.lfs.2015.01.013
• 15 Misra S, Kuhad A, Chopra K. Neurobiological effect of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in experimental paradigm of Alzheimer’s disease. Indian J Exp Biol 2013; 51: 1086-1093
• 16 Sachdeva AK, Misra S, Pal Kaur I et al. Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: Behavioral and biochemical evidence. Eur J Pharmacol 2015; 747: 132–140 doi:10.1016/j.ejphar.2014.11.014
• 17 Paxinos G, Watson CR, Emson PC. AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980; 3: 129-149
• 18 Dhingra D, Chillar R. Antidepressant-like activity of ellagic acid in unstressed and acute immobilization-induced stressed mice. Pharmacol Rep 2012; 64: 796-807
• 19 Sonkusare S, Srinivasan K, Kaul C. et al. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 2005; 77: 1-14
• 20 Snyder PJ, Bednar MM, Cromer JR. et al. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 2005; 1: 126-135 10.1016/j.jalz.2005.09.004
• 21 Matsui K, Mishima M, Nagai Y. et al. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos 1999; 27: 1406-1414
• 22 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358
• 23 Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77
• 24 Rakieten N, Rakieten ML, Nadkarni MR. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: 91-98
• 25 Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res 2007; 125: 451-472
• 26 Rai S, Kamat PK, Nath C. et al. Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav 2014; 117: 104-117 10.1016/j.pbb.2013.11.035
• 27 Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1: 848-858
• 28 Keller JN, Schmitt FA, Scheff SW. et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005; 64: 1152-1156
• 29 Lovell MA, Ehmann WD, Butler SM. et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995; 45: 1594-1601
• 30 Mandal PK, Tripathi M, Sugunan S. Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 2012; 417: 43-48 10.1016/j.bbrc.2011.11.047
• 31 Tiwari V, Kuhad A, Bishnoi M. et al. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav 2009; 93: 183-189 10.1016/j.pbb.2009.05.009
• 32 Choi DY, Lee YJ, Hong JT. et al. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 2012; 87: 144-153 10.1016/j.brainresbull.2011.11.014
• 33 Tan ZS, Beiser AS, Vasan RS. et al. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 2007; 68: 1902-1908
• 34 Cheng X, Shen Y, Li R. et al. Targeting TNF: A therapeutic strategy for Alzheimer’s disease. Drug Discov Today 2014; 19: 1822-1827 10.1016/j.drudis.2014.06.029